S

Sanofi

Global pharma company; vaccines and R&D

Associate Director Retail Marketing

Full-TimeUpdated on 10/23/2026Deadline 11/30/26
$148.5k - $214.5k
Expert
Bachelor's, Master's, MBA
Moosic, PA, USA
In PersonBased in Moosic, PA; travel approximately 25–30%.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree is required.
  • A minimum of 5 years of experience in pharmaceutical, healthcare, biotech, or vaccine marketing, sales, strategy, or related agency experience is required.
  • Demonstrated strategic thinking and formal presentation development, with strong interpersonal, verbal, and written presentation skills.
  • Ability to lead, influence, and drive results across matrixed organizations without direct authority.
  • Ability to own initiatives from beginning to end with attention to detail.
  • High personal and professional integrity and a strong work ethic in a fast-paced environment.
  • Ability to travel approximately 25–30%.
  • Knowledge of the United States legal-regulatory environment affecting appropriate promotional activities.
  • Ability to navigate promotional materials through legal, regulatory, and medical review processes.
Responsibilities
  • Lead tactical execution of retail marketing and identify efficiencies across multiple franchises to optimize performance and resource allocation.
  • Partner with cross-functional teams in franchise-related planning and budgeting to identify growth opportunities and ensure end-to-end execution.
  • Meet with influential contacts within top retailers to expand VaxServe reach and influence through marketing campaigns.
  • Champion retail segment strategy pull-through to drive uptake in top targeted accounts and deliver VaxServe P&L performance.
  • Act as field integration lead with the Retail sales team to ensure strategic pull-through, provide support, identify education needs, and uncover opportunities.
  • Apply knowledge of the retail vaccine market and trends to form long-term strategies and solutions.
  • Oversee management of the Agency of Record and other vendor partners.
  • Measure, monitor, evaluate, and report on retail marketing program effectiveness to inform investment decisions.
  • Lead the development, creation, and implementation of branded and unbranded promotional materials.
  • Manage promotional submissions through legal, regulatory, and medical review processes and coordinate with agencies to ensure deliverables are met for retail marketing materials.
  • Ensure marketing processes, documents, and tactics comply with Sanofi and VaxServe corporate requirements.
  • Develop and manage the promotional budget and monitor the productivity of promotional programs.
  • Lead cross-functional retail strategy meetings with brand marketing, market research, market access, legal, regulatory, and other functions.
  • Support annual retail conference planning and coordinate with attendees on related promotional materials and presentations.
Desired Qualifications
  • Experience managing creative agencies and third-party vendors to deliver results.
  • A master's degree, including an MBA or a degree in a related field.
  • Vaccine and marketing experience with Retail Pharmacy.
  • Ability to travel approximately 25–30%.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...